Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mindy M Mickelson

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Diabetes : a Publication of the American Diabetes Association|July 17, 2024
Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods StudyElizabeth H Golembiewski, Andrea E Garcia Bautista, Eric Polley, et al.
Diabetes Research and Clinical Practice|September 22, 2025
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trialStacey M Sklepinski, Yihong Deng, Kavya Sindu Swarna, et al.
JAMA Otolaryngology-- Head & Neck Surgery|January 23, 2025
GLP-1RA Use and Thyroid Cancer RiskJuan P Brito, Jeph Herrin, Kavya Sindhu Swarna, et al.
JACC. Advances|June 28, 2024
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 DiabetesRozalina G McCoy, Kavya Sindhu Swarna, Yihong Deng, et al.
BMJ Open Diabetes Research & Care|May 21, 2026
Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulationStacey Sklepinski, Alexandria A Ratzki-Leewing, Jeph Herrin, et al.
Nature Cardiovascular Research|June 7, 2024
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular riskRozalina G McCoy, Jeph Herrin, Kavya Sindhu Swarna, et al.
Journal of the American Heart Association|May 14, 2026
Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target TrialAnum Zehra, Yihong Deng, Kavya Sindhu Swarna, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 10, 2026
Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness StudyUrja N Kalathiya, Kimberly Yuang, Jeph Herrin, et al.
BMJ Open Diabetes Research & Care|February 27, 2026
Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulationStacey Sklepinski, Alexandria A Ratzki-Leewing, Jeph Herrin, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Diabetes : a Publication of the American Diabetes Association|July 17, 2024
Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods StudyElizabeth H Golembiewski, Andrea E Garcia Bautista, Eric Polley, et al.
Diabetes Research and Clinical Practice|September 22, 2025
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trialStacey M Sklepinski, Yihong Deng, Kavya Sindu Swarna, et al.
JAMA Otolaryngology-- Head & Neck Surgery|January 23, 2025
GLP-1RA Use and Thyroid Cancer RiskJuan P Brito, Jeph Herrin, Kavya Sindhu Swarna, et al.
JACC. Advances|June 28, 2024
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 DiabetesRozalina G McCoy, Kavya Sindhu Swarna, Yihong Deng, et al.
BMJ Open Diabetes Research & Care|May 21, 2026
Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulationStacey Sklepinski, Alexandria A Ratzki-Leewing, Jeph Herrin, et al.
Nature Cardiovascular Research|June 7, 2024
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular riskRozalina G McCoy, Jeph Herrin, Kavya Sindhu Swarna, et al.
Journal of the American Heart Association|May 14, 2026
Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target TrialAnum Zehra, Yihong Deng, Kavya Sindhu Swarna, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 10, 2026
Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness StudyUrja N Kalathiya, Kimberly Yuang, Jeph Herrin, et al.
BMJ Open Diabetes Research & Care|February 27, 2026
Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulationStacey Sklepinski, Alexandria A Ratzki-Leewing, Jeph Herrin, et al.
Pageof 2